ANI Pharmaceuticals Inc(ANIP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:47 AM ET (Korea 9/11 17:47)
Full metrics table
| Index | RUT | P/E | 15.4 | EPS (ttm) | 4.63 | Insider Own | 12.17% | Shs Outstand | 23.0M | Perf Week | -2.34% |
| Market Cap | 1.64B | Forward P/E | 6.81 | EPS next Y | 12.89% | Insider Trans | -4.15% | Shs Float | 20.2M | Perf Month | -4.27% |
| Enterprise Value | 1.87B | PEG | 0.46 | EPS next Q | 2.16 | Inst Own | 101.32% | Short Float | 16.96% | Perf Quarter | -12.83% |
| Income | 0.10B | P/S | 1.68 | EPS this Y | 17.71% | Inst Trans | -2.04% | Short Ratio | 10.01 | Perf Half Y | -6.48% |
| Sales | 0.98B | P/B | 2.74 | EPS next 5Y | 14.91% | ROA | 7.05% | Short Interest | 3.42M | Perf YTD | -9.61% |
| Book/sh | 26 | P/C | 4.36 | EPS past 3/5Y | - | ROE | 19.33% | 52W High | -28.29% ($99.50) | Perf Year | -26.79% |
| Cash/sh | 16.36 | P/FCF | 9.47 | Sales past 3/5Y | 40.81% 33.48% | ROIC | 8.42% | 52W Low | 1.99% ($69.96) | Perf 3Y | 15.19% |
| Dividend Est. | - | EV/EBITDA | 8.66 | EPS Y/Y TTM | 743.87% | Gross Margin | 51.63% | Volatility(W/M) | 1.95% 2.69% | Perf 5Y | 160.02% |
| Dividend TTM | - | EV/Sales | 1.91 | Sales Y/Y TTM | 30.9% | Oper. Margin | 13.34% | ATR (14) | 2.06 | Perf 10Y | 18.66% |
| Dividend Ex-Date | - | Quick Ratio | 2.4 | EPS Q/Q | 191.09% | Profit Margin | 10.18% | RSI (14) | 38.45 | Recom | 1.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.91 | Sales Q/Q | 25.87% | SMA20 | -3.54% ($73.97) | Beta | 0.5 | Target Price | $108.38 |
| Payout | - | Debt/Eq | 1.02 | Earnings | 2026/8/7 | SMA50 | -8.3% ($77.81) | Rel Volume | 0.67 | Prev Close | $70.7 |
| Employees | 970 | LT Debt/Eq | 0.99 | EPS/Sales Surpr. | 8.2% 2.27% | SMA200 | -9.89% ($79.18) | Avg Volume(3M) | 0.34M | Price | $71.35 |
| IPO | 2000/5/12 | Option/Short | Yes/Yes | Trades | 4990 | Volume | 228,885 | Change | 0.92% |
Company
ANIP is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 This is a US pharmaceutical company that develops and sells treatments for rare diseases along with specialty and generic drugs. It maintains a diversified portfolio spanning rare disease branded medications, specialty pharmaceuticals, and generic drugs, and is working to grow its rare disease business as a key growth engine. The company has established itself as a diversified pharmaceutical operator that combines rare disease, specialty, and generic drug businesses.
Over the past 1 year, on the lower side
28% below its 1-year high.
ANIP makes money exceptionally well
Strong earnings and excellent financial health
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.7% this year.
Tap to view numbers
The price looks about right
Trading at 15.4 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +15.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 101.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PJP 0.03%
XPH 0.02%
PILL 0.01%
RZG 0.01%
JSML 0.01%It ranks #4 in the industry
Based on market cap of $2B.
ANIP $2B PER 15.4
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is ANIP?
ANIP belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ANIP?
The market cap of ANIP is approximately $1.6B, ranking 2,279 within its sector.
What is the P/E ratio of ANIP?
ANIP has a P/E ratio of approximately 15.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ANIP?
ANIP has recorded a 52-week high of $99.50 and a low of $69.96.
